目的 系统评价索利那新联合坦索罗辛治疗Ⅲ型前列腺炎的临床疗效。方法 计算机检索PubMed、EMbase、Cochrane Library、中国生物医学文献数据库（CBM）、中国期刊全文数据库（CNKI）、中文科技期刊全文数据库（VIP）和万方数据库，收集索利那新联合坦索罗辛治疗Ⅲ型前列腺炎的随机对照试验（RCT），检索时限2000年1月-2017年6月。采用Cochrane协作网推荐的RevMan 5.3软件对各效应指标进行Meta分析。结果 共纳入9项RCTs，计938例Ⅲ型前列腺炎患者。Meta分析结果显示，联合用药组痊愈率[OR=1.82，95%CI（1.30，2.56），P=0.000 5]与总有效率[OR=4.46，95%CI（2.86，6.95），P < 0.001]均显著高于对照组，差异有统计学意义（P < 0.05）；联合用药组NIH-CPSI评分、疼痛症状评分、排尿症状评分、生活质量评分均显著低于对照组，差异有统计学意义（P < 0.05）。结论 索利那新联合坦索罗辛治疗Ⅲ型前列腺炎较单用坦索罗辛的临床效果好。受纳入文献的质量和样本量限制，上述结论尚待更多大样本、高质量的研究予以进一步证实。

Objective To evaluate the efficacy of solifenacin combined with tamsulosin in the treatment of type III prostatitis. Methods The randomized controlled trials (RCT) of solifenacin combined with tamsulosin in the treatment of type III prostatitis were searched from PubMed, EMbase, Cochrane Library, CBM, CNKI, VIP database, and Wangfang detabase. Data were collected from January 2000 to June 2017 and also retrieved manually. At the same time, Meta analysis was carried out by using RevMan 5.3 software. Results A total of nine RCTs were included, including 938 patients with type III prostatitis. Meta analysis results showed that the cure rate[OR=1.82, 95%CI (1.30, 2.56), P=0.000 5] and effective rate[OR=4.46, 95%CI (2.86, 6.95), P < 0.001] of treatment group were significantly higher than those in control group. Moreover, NIH-CPSI score, symptom of pain score, voiding symptom score and life quality score of treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Solifenacin combined with tamsulosin in the treatment of type III prostatitis has better effect than tamsulosin monotherapy. However, there is limit of methodological quality and sample size, so more RCTs with high quality, large sample, and long-term follow up are required for further verification.